×
About 1,050,810 results

Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function
https://clinicaltrials.gov/ct2/show/NCT02743468

Jul 1st, 2022 - This is a prospective, cross-sectional study designed to provide a consistent method for obtaining biological samples and respiratory health-related information from participants for use in research that evaluates lung function (e.g., responses to environmental agents such as air pollution particles, engineered nanomaterials, or immune ligands; the role of genetics on cellular responses or func...

Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors
https://clinicaltrials.gov/ct2/show/NCT04450927

Jul 1st, 2022 - This protocol is designed to provide a repository of information to allow for hypothesis generation in future research. This information will be drawn from standard medical care/procedures and follow up of patients and healthy volunteers, including transplant donors, who are not currently receiving therapy on an active NHLBI research protocol. It allows investigation into the problems of these ...

Fusion Guided Focal Laser Ablation of Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02759744

Jul 1st, 2022 - Background: Pilot study to evaluate the feasibility of real time ultrasound imaging to guide focal thermal ablation of low risk focal prostate tumors Prostate cancer is relatively slow growing, with doubling times for local tumors estimated at 2 to 4 years. Recent patient series suggest that 20% to 30% of men undergoing radical prostatectomy have pathologic features in the radical prostatectomy...

Clinical and Molecular Studies in Families With Inherited Eye Disease
https://clinicaltrials.gov/ct2/show/NCT02771236

Jul 1st, 2022 - Objective: This project, Clinical and Molecular Studies in Families with Inherited Eye Disease will study inherited eye diseases, both Mendelian and complex age related inherited eye diseases, in families of many nationalities and ethnic backgrounds in order to identify the genes that, when mutated, cause inherited eye diseases and the pathophysiology through which they act. Among the diseases ...

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
https://clinicaltrials.gov/ct2/show/NCT04468958

Jul 1st, 2022 - There were 4 treatment groups and 1 control group. Cohort 1 received 1 dose of SAB-185 at 10 mg/kg per dose. Cohort 2 received 1 dose of SAB-185 at 25 mg/kg, Cohort 3 received 2 doses of SAB-185 at 25 mg/kg each 7 days apart, and Cohort 4 received 1 dose of SAB-185 at 50 mg/kg per dose. All the doses were prepared at the site by the pharmacy staff or designee for delivery to the clinical staff ...

New Technology and Child Health
https://clinicaltrials.gov/ct2/show/NCT02622035

Jul 1st, 2022 - Background: We are involved in testing new behavioral science methods and measures for future research projects. In the course of these evaluations, we will also test research questions related to parents psychological experiences and how these relate to the responses they have when they encounter different types of communication about child health. We are testing multiple research questions in...

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
https://clinicaltrials.gov/ct2/show/NCT00242723

Jul 1st, 2022 - Background: Lung and esophageal cancers as well as malignant pleural mesotheliomas exhibit epigenetic perturbations that may impact the clinical course of these neoplasms. To date, epigenetic alterations in primary thoracic malignancies and neoplasms metastatic to the chest have not been evaluated in a systematic, longitudinal manner. Objectives: To permit evaluation of patients referred to the...

Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
https://clinicaltrials.gov/ct2/show/NCT04442425

Jul 1st, 2022 - Background: Pain related to cancer/tumors can be widespread, wield debilitating effects on daily life, and interfere with otherwise positive outcomes from targeted treatment. The underpinnings of this study are chiefly motivated by the need to develop and validate objective methods for measuring pain using a model that is relevant in breadth and depth to a diversity of patient populations. Inad...

All Polyethylene Tibia-VEGA Kiel
https://clinicaltrials.gov/ct2/show/NCT02756702

Jul 1st, 2022 - This non-interventional clinical study (NIS) is conducted to clinically confirm the safety and performance of the Aesculap® APT VEGA System® PS components under routine conditions. The VEGA System® PS is an established TKA design, and there is a long-lasting experience in the use of PE for TKA in general and for APT components in particular; thus a NIS is thought to be sufficient to give the re...

Baltimore Longitudinal Study of Aging
https://clinicaltrials.gov/ct2/show/NCT00233272

Jul 1st, 2022 - The Baltimore Longitudinal Study of Aging (BLSA) is the NIA s major clinical research program in human aging that has been conducted in Baltimore since 1958. The study population is a series of healthy volunteers of different ages followed indefinitely with serial evaluations over time. The major aim of the study is to characterize the aging process in its multifaceted aspects. To accomplish th...

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
https://clinicaltrials.gov/ct2/show/NCT02759835

Jul 1st, 2022 - Background: EGFR tyrosine kinase inhibitors (TKI) have significantly improved the response rate (RR) and survival in patients with tumors harboring EGFR-sensitizing mutations. An invariable consequence of treatment with EGFR-TKIs is the development of acquired resistance. The most common mechanism of resistance observed in approximately 50% of all cases is the emergence of a secondary mutation ...

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
https://clinicaltrials.gov/ct2/show/NCT02759731

Jul 1st, 2022 - Background: Chronic graft-versus-host disease (cGVHD) is the leading cause of non-relapse morbidity and mortality in persons after allogeneic hematopoietic stem cell transplantation (SCT). Approximately 50% of patients with cGVHD have disease refractory to systemic corticosteroids; currently, there is no standard second-line therapy. The JAK-STAT pathway relays the signaling function of several...

Phase 1 Study of SAR440894 vs Placebo
https://clinicaltrials.gov/ct2/show/NCT04441905

Jul 1st, 2022 - A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at one US site. Each subject will be randomized to receive either SAR440894 or matching placebo via 60-minute intravenous infusion. In each cohort of 8 subjects, the randomization ratio will be 6 active to 2 placebo, and 2 sentinel subjects (one fro...

Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
https://clinicaltrials.gov/ct2/show/NCT02741440

Jul 1st, 2022 - Objective: Spinocerebellar Ataxia, type 7 (SCA7) is an autosomal dominant neurodegenerative disease characterized by progressive ataxia, retinal degeneration, and marked genetic anticipation. The objectives of this study are to 1) establish a cohort of participants with molecularly-confirmed SCA7 in anticipation of future clinical trials, 2) create a repository of plasma, DNA, and skin fibrobla...

Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
https://clinicaltrials.gov/ct2/show/NCT04448184

Jul 1st, 2022 - In Canada, over 1,500 autologous hematopoietic stem cell transplantations (ASCT) are performed annually for hematologic malignancies. It is currently standard practice to provide a prophylactic transfusion of platelets to prevent bleeding when the daily measured platelet count is less than 10 x 109/L. A patient may require up to six adult platelet doses during the post-transplant period. Howeve...

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
https://clinicaltrials.gov/ct2/show/NCT04449549

Jul 1st, 2022 - Background: Rare tumors constitute a heterogeneous group of cancers associated with limited treatment options and poor outcomes. Due to their rarity, there are few good models for these diseases to support preclinical evaluation of new anticancer agents. To address these challenges, DCTD s Patient-Derived Models Repository (PDMR) is generating patient-derived xenograft models of adult and pedia...

Natural History Study of Patients With Excess Androgen
https://clinicaltrials.gov/ct2/show/NCT00250159

Jul 1st, 2022 - Androgen excess in childhood results in pseudoprecocious puberty, accelerated childhood growth with premature epiphyseal fusion, adult short stature, and unknown metabolic and psychological perturbations. Congenital adrenal hyperplasia (CAH) and familial male-limited precocious puberty (FMPP) are two genetic diseases that result in early childhood androgen excess, and CAH due to 21-hydroxylase ...

Links Between Inflammation and Cardiometabolic Diseases
https://clinicaltrials.gov/ct2/show/NCT01934660

Jul 1st, 2022 - Over the past two decades, the number of subjects with cardiometabolic diseases (CMD) such as atherosclerotic cardiovascular disease (CVD), dyslipidemia, insulin resistance and diabetes have been rising. Characterizing these disease states reveals that inflammation is a common feature of CMD; however, mechanistic links between inflammation and these disease states in humans remain poorly unders...

Physiological Investigations of Movement Disorders
https://clinicaltrials.gov/ct2/show/NCT01019343

Jul 1st, 2022 - Objectives The purpose of this protocol is to improve understanding of the pathophysiology of movement disorders by performing small behavioral, electrophysiological and neuroimaging sub-studies. This will allow identifying dysfunction of the central nervous system that causes behavioral abnormalities seen in movement disorder patients. This will also help to determine potential diagnostic or t...

Evaluating a New Knee-Ankle-Foot Brace to Improve Gait in Children With Movement Disorders
https://clinicaltrials.gov/ct2/show/NCT01961557

Jul 1st, 2022 - Objective The purpose of this protocol is to evaluate several configurations of a prototype Extension Assist Knee-Ankle-Foot Orthosis (EA-KAFO) in patients with cerebral palsy (CP), muscular dystrophy (MD), spina bifida (SB), or incomplete spinal cord injury (iSCI) who have knee extension deficiency. Three forms of assistance will be provided at the knee joint including a passive-damper compone...